Print

Active Biotech postpone publication of the interim report

2016-10-26

Active Biotech has decided to postpone the publication of the interim report for January-September 2016 to November 11, 2016, after stock markets closing. Previously communicated date was November 10, 2016.

Lund October 26, 2016

For further information, please contact
Hans Kolam, CFO
Tel. +46 46 19 20 44

Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties, is in pivotal Phase 3 development for the treatment of relapsing remitting multiple sclerosis. Also, laquinimod is in Phase 2 development for the treatment of primary progressive multiple sclerosis and Huntington's disease. Furthermore, commercial activities are conducted for the tasquinimod, SILC, ANYARA and paquinimod projects. Please visit www.activebiotech.com for more information.

Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00


pdf161026_new date_Q3



Back